Research ArticleDrug Discovery and Translational Medicine
In Vitro Pharmacological Characterization and In Vivo Validation of LSN3172176 a Novel M1 Selective Muscarinic Receptor Agonist Tracer Molecule for Positron Emission Tomography
Adrian J. Mogg, Thomas Eessalu, Megan Johnson, Rebecca Wright, Helen E. Sanger, Hongling Xiao, Michael G. Crabtree, Alex Smith, Ellen M. Colvin, Douglas Schober, Donald Gehlert, Cynthia Jesudason, Paul J. Goldsmith, Michael P. Johnson, Christian C. Felder, Vanessa N. Barth and Lisa M. Broad
Journal of Pharmacology and Experimental Therapeutics June 2018, 365 (3) 602-613; DOI: https://doi.org/10.1124/jpet.117.246454
Adrian J. Mogg
Eli Lilly & Co. Ltd., Lilly Research Centre, Windlesham, Surrey, United Kingdom (A.J.M., H.E.S., M.G.C., A.S., E.M.C., P.J.G., L.M.B.) and Eli Lilly & Co. Ltd., Lilly Corporate Center, Indianapolis, Indiana (T.E., M.J., R.W., H.X., D.S., D.G., C.J., M.P.J., C.C.F., V.N.B.)
Thomas Eessalu
Eli Lilly & Co. Ltd., Lilly Research Centre, Windlesham, Surrey, United Kingdom (A.J.M., H.E.S., M.G.C., A.S., E.M.C., P.J.G., L.M.B.) and Eli Lilly & Co. Ltd., Lilly Corporate Center, Indianapolis, Indiana (T.E., M.J., R.W., H.X., D.S., D.G., C.J., M.P.J., C.C.F., V.N.B.)
Megan Johnson
Eli Lilly & Co. Ltd., Lilly Research Centre, Windlesham, Surrey, United Kingdom (A.J.M., H.E.S., M.G.C., A.S., E.M.C., P.J.G., L.M.B.) and Eli Lilly & Co. Ltd., Lilly Corporate Center, Indianapolis, Indiana (T.E., M.J., R.W., H.X., D.S., D.G., C.J., M.P.J., C.C.F., V.N.B.)
Rebecca Wright
Eli Lilly & Co. Ltd., Lilly Research Centre, Windlesham, Surrey, United Kingdom (A.J.M., H.E.S., M.G.C., A.S., E.M.C., P.J.G., L.M.B.) and Eli Lilly & Co. Ltd., Lilly Corporate Center, Indianapolis, Indiana (T.E., M.J., R.W., H.X., D.S., D.G., C.J., M.P.J., C.C.F., V.N.B.)
Helen E. Sanger
Eli Lilly & Co. Ltd., Lilly Research Centre, Windlesham, Surrey, United Kingdom (A.J.M., H.E.S., M.G.C., A.S., E.M.C., P.J.G., L.M.B.) and Eli Lilly & Co. Ltd., Lilly Corporate Center, Indianapolis, Indiana (T.E., M.J., R.W., H.X., D.S., D.G., C.J., M.P.J., C.C.F., V.N.B.)
Hongling Xiao
Eli Lilly & Co. Ltd., Lilly Research Centre, Windlesham, Surrey, United Kingdom (A.J.M., H.E.S., M.G.C., A.S., E.M.C., P.J.G., L.M.B.) and Eli Lilly & Co. Ltd., Lilly Corporate Center, Indianapolis, Indiana (T.E., M.J., R.W., H.X., D.S., D.G., C.J., M.P.J., C.C.F., V.N.B.)
Michael G. Crabtree
Eli Lilly & Co. Ltd., Lilly Research Centre, Windlesham, Surrey, United Kingdom (A.J.M., H.E.S., M.G.C., A.S., E.M.C., P.J.G., L.M.B.) and Eli Lilly & Co. Ltd., Lilly Corporate Center, Indianapolis, Indiana (T.E., M.J., R.W., H.X., D.S., D.G., C.J., M.P.J., C.C.F., V.N.B.)
Alex Smith
Eli Lilly & Co. Ltd., Lilly Research Centre, Windlesham, Surrey, United Kingdom (A.J.M., H.E.S., M.G.C., A.S., E.M.C., P.J.G., L.M.B.) and Eli Lilly & Co. Ltd., Lilly Corporate Center, Indianapolis, Indiana (T.E., M.J., R.W., H.X., D.S., D.G., C.J., M.P.J., C.C.F., V.N.B.)
Ellen M. Colvin
Eli Lilly & Co. Ltd., Lilly Research Centre, Windlesham, Surrey, United Kingdom (A.J.M., H.E.S., M.G.C., A.S., E.M.C., P.J.G., L.M.B.) and Eli Lilly & Co. Ltd., Lilly Corporate Center, Indianapolis, Indiana (T.E., M.J., R.W., H.X., D.S., D.G., C.J., M.P.J., C.C.F., V.N.B.)
Douglas Schober
Eli Lilly & Co. Ltd., Lilly Research Centre, Windlesham, Surrey, United Kingdom (A.J.M., H.E.S., M.G.C., A.S., E.M.C., P.J.G., L.M.B.) and Eli Lilly & Co. Ltd., Lilly Corporate Center, Indianapolis, Indiana (T.E., M.J., R.W., H.X., D.S., D.G., C.J., M.P.J., C.C.F., V.N.B.)
Donald Gehlert
Eli Lilly & Co. Ltd., Lilly Research Centre, Windlesham, Surrey, United Kingdom (A.J.M., H.E.S., M.G.C., A.S., E.M.C., P.J.G., L.M.B.) and Eli Lilly & Co. Ltd., Lilly Corporate Center, Indianapolis, Indiana (T.E., M.J., R.W., H.X., D.S., D.G., C.J., M.P.J., C.C.F., V.N.B.)
Cynthia Jesudason
Eli Lilly & Co. Ltd., Lilly Research Centre, Windlesham, Surrey, United Kingdom (A.J.M., H.E.S., M.G.C., A.S., E.M.C., P.J.G., L.M.B.) and Eli Lilly & Co. Ltd., Lilly Corporate Center, Indianapolis, Indiana (T.E., M.J., R.W., H.X., D.S., D.G., C.J., M.P.J., C.C.F., V.N.B.)
Paul J. Goldsmith
Eli Lilly & Co. Ltd., Lilly Research Centre, Windlesham, Surrey, United Kingdom (A.J.M., H.E.S., M.G.C., A.S., E.M.C., P.J.G., L.M.B.) and Eli Lilly & Co. Ltd., Lilly Corporate Center, Indianapolis, Indiana (T.E., M.J., R.W., H.X., D.S., D.G., C.J., M.P.J., C.C.F., V.N.B.)
Michael P. Johnson
Eli Lilly & Co. Ltd., Lilly Research Centre, Windlesham, Surrey, United Kingdom (A.J.M., H.E.S., M.G.C., A.S., E.M.C., P.J.G., L.M.B.) and Eli Lilly & Co. Ltd., Lilly Corporate Center, Indianapolis, Indiana (T.E., M.J., R.W., H.X., D.S., D.G., C.J., M.P.J., C.C.F., V.N.B.)
Christian C. Felder
Eli Lilly & Co. Ltd., Lilly Research Centre, Windlesham, Surrey, United Kingdom (A.J.M., H.E.S., M.G.C., A.S., E.M.C., P.J.G., L.M.B.) and Eli Lilly & Co. Ltd., Lilly Corporate Center, Indianapolis, Indiana (T.E., M.J., R.W., H.X., D.S., D.G., C.J., M.P.J., C.C.F., V.N.B.)
Vanessa N. Barth
Eli Lilly & Co. Ltd., Lilly Research Centre, Windlesham, Surrey, United Kingdom (A.J.M., H.E.S., M.G.C., A.S., E.M.C., P.J.G., L.M.B.) and Eli Lilly & Co. Ltd., Lilly Corporate Center, Indianapolis, Indiana (T.E., M.J., R.W., H.X., D.S., D.G., C.J., M.P.J., C.C.F., V.N.B.)
Lisa M. Broad
Eli Lilly & Co. Ltd., Lilly Research Centre, Windlesham, Surrey, United Kingdom (A.J.M., H.E.S., M.G.C., A.S., E.M.C., P.J.G., L.M.B.) and Eli Lilly & Co. Ltd., Lilly Corporate Center, Indianapolis, Indiana (T.E., M.J., R.W., H.X., D.S., D.G., C.J., M.P.J., C.C.F., V.N.B.)
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticleDrug Discovery and Translational Medicine
A Novel M1 Selective Muscarinic Receptor Agonist for PET
Adrian J. Mogg, Thomas Eessalu, Megan Johnson, Rebecca Wright, Helen E. Sanger, Hongling Xiao, Michael G. Crabtree, Alex Smith, Ellen M. Colvin, Douglas Schober, Donald Gehlert, Cynthia Jesudason, Paul J. Goldsmith, Michael P. Johnson, Christian C. Felder, Vanessa N. Barth and Lisa M. Broad
Journal of Pharmacology and Experimental Therapeutics June 1, 2018, 365 (3) 602-613; DOI: https://doi.org/10.1124/jpet.117.246454
Research ArticleDrug Discovery and Translational Medicine
A Novel M1 Selective Muscarinic Receptor Agonist for PET
Adrian J. Mogg, Thomas Eessalu, Megan Johnson, Rebecca Wright, Helen E. Sanger, Hongling Xiao, Michael G. Crabtree, Alex Smith, Ellen M. Colvin, Douglas Schober, Donald Gehlert, Cynthia Jesudason, Paul J. Goldsmith, Michael P. Johnson, Christian C. Felder, Vanessa N. Barth and Lisa M. Broad
Journal of Pharmacology and Experimental Therapeutics June 1, 2018, 365 (3) 602-613; DOI: https://doi.org/10.1124/jpet.117.246454
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement